We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Adding Baricitinib to COVID-19 Treatment Reduces Mortality by 44 Percent
Adding Baricitinib to COVID-19 Treatment Reduces Mortality by 44 Percent
Mechanically ventilated patients with COVID-19 were 44 percent less likely to die when Olumiant (baricitinib) was added to the standard treatment regimen, according to a substudy of Eli Lilly’s COV-BARRIER trial.